×
Pfizer Cash on Hand 2010-2024 | PFE
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Pfizer cash on hand for the quarter ending June 30, 2024 was
$7.100B
, a
84.15% decline
year-over-year.
Pfizer cash on hand for 2023 was
$12.69B
, a
44.18% decline
from 2022.
Pfizer cash on hand for 2022 was
$22.732B
, a
26.83% decline
from 2021.
Pfizer cash on hand for 2021 was
$31.069B
, a
154.18% increase
from 2020.
View More
Pfizer Cash on Hand 2010-2024 | PFE
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Pfizer cash on hand for 2023 was
$12.69B
, a
44.18% decline
from 2022.
Pfizer cash on hand for 2022 was
$22.732B
, a
26.83% decline
from 2021.
Pfizer cash on hand for 2021 was
$31.069B
, a
154.18% increase
from 2020.
Related Stocks
Company Name
Market
Cap
Eli Lilly (LLY)
$861.3B
Novo Nordisk (NVO)
$592.4B
Johnson & Johnson (JNJ)
$402.2B
AbbVie (ABBV)
$341.7B
Merck (MRK)
$299.6B
AstraZeneca (AZN)
$243.5B
Novartis AG (NVS)
$236.5B
Sanofi (SNY)
$144.1B
Innoviva (INVA)
$1.2B